Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Penn Microbiome Therapy - 001
- Development stage
- Unknown
- Lead developer
- University of Pennsylvania
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Penn Microbiome Therapy - 001 (PMT-001) is a fecal microbiota transplant (FMT) biologic product developed by the University of Pennsylvania for the treatment of severe and severe-complicated/fulminant Clostridium difficile infection (CDI). The therapy consists of a diverse community of live microorganisms derived from healthy donor stool, intended to restore a balanced intestinal microbiome and re-establish colonization resistance against C. difficile. It has been evaluated in Phase II clinical trials (NCT03970200) as an adjunctive treatment to standard antibiotic therapy to improve clinical outcomes in patients with life-threatening CDI.
- Other names
- Penn Microbiome Therapy 001
Beyond the preview
Go deeper on Penn Microbiome Therapy - 001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Penn Microbiome Therapy - 001.